✦ LIBER ✦

Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?

✍ Scribed by Thomas Berg; Christoph Sarrazin; Holger Hinrichsen; Peter Buggisch; Tilman Gerlach; Reinhart Zachoval; Stefan Zeuzem

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 93 KB
Volume: 39
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.20226

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SAFE biopsy: A validated method for larg

SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C

✍ Giada Sebastiani; Philippe Halfon; Laurent Castera; Stanislas Pol; David L. Thom 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 226 KB 👁 1 views

The staging of liver fibrosis is pivotal for defining the prognosis and indications for therapy in hepatitis C. Although liver biopsy remains the gold standard, several noninvasive methods are under evaluation for clinical use. The aim of this study was to validate the recently described sequential

Limitations of the algorithm for the SAF

Limitations of the algorithm for the SAFE biopsy: A noninvasive fibrosis measure in chronic hepatitis C

✍ Mohammed Rashid; Jonathon D. Mitchell; Matthew E. Cramp; Timothy J. S. Cross 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 1 views

Simple blood tests as noninvasive marker

Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection

✍ Leonardo L. Schiavon; Janaína L. N. Schiavon; Roberto J. Carvalho Filho; Juliana 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB 👁 2 views

HCV infection is common among patients with end-stage renal disease (ESRD) on hemodialysis, and it has been considered an independent risk factor for mortality in this setting. Although liver biopsy in ESRD patients with HCV infection is useful before kidney transplantation, it carries a high risk o